Europe — EMA
Octanate (Human Coagulation Factor Viii)
Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use.
Request sourcing
What is Human Coagulation Factor Viii?
Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use. It replaces deficient factor VIII in patients with hemophilia A, helping to control bleeding episodes. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.
GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.
What is Human Coagulation Factor Viii used for?
Octanate is used in the management of inherited bleeding disorders that involve the coagulation cascade, particularly hemophilia A. - Hemophilia A (severe): Provides factor VIII replacement to prevent or control bleeding episodes. - Hemophilia A (moderate): Supports routine prophylaxis to reduce frequency of bleeds. - Hemophilia A (mild) and other factor VIII deficiencies: Supplies the missing factor VIII to achieve hemostasis.
What are the side effects of Human Coagulation Factor Viii?
Octanate may exhibit the following effects:
Common Side Effects: - C ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .... ... ... … - … - … ... - … - .... - ...
Serious or Rare Slight ... ":[ ",
